We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Location Sciences Group Plc | LSE:LSAI | London | Ordinary Share | GB00BGT36S19 | ORD 0.1P |
Bid Price | Offer Price | High Price | Low Price | Open Price | |
---|---|---|---|---|---|
0.20 | 0.23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Mgmt Invt Offices, Open-end | 53k | -1.72M | -0.2257 | -5.95 | 10.27M |
Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
---|---|---|---|---|
- | O | 0 | 134.375 | GBX |
Date | Time | Source | Headline |
---|---|---|---|
19/2/2024 | 08:00 | UK RNS | AIM Readmission - Location Sciences Group Plc |
16/2/2024 | 12:30 | UK RNS | Location Sciences Group PLC Result of General Meeting |
06/2/2024 | 10:55 | UK RNS | Location Sciences Group PLC Holding(s) in Company |
30/1/2024 | 10:37 | ALNC | Location Sciences shares surge on Sorted reverse takeover |
30/1/2024 | 08:00 | UK RNS | AIM Schedule One - Location Sciences Group Plc |
30/1/2024 | 07:30 | UK RNS | AIM Restoration - Location Sciences Group PLC |
30/1/2024 | 07:00 | UK RNS | Location Sciences Group PLC Acquisition and Publication of Admission.. |
25/1/2024 | 21:59 | ALNC | TRADING UPDATES: Karelian gets permit extension, Starwood ups dividend |
25/1/2024 | 07:00 | UK RNS | Location Sciences Group PLC Loan Facility and Holding in Company |
20/12/2023 | 20:00 | ALNC | TRADING UPDATES: K3 Business says cash balances ahead of forecast |
Location Sciences (LSAI) Share Charts1 Year Location Sciences Chart |
|
1 Month Location Sciences Chart |
Intraday Location Sciences Chart |
Date | Time | Title | Posts |
---|---|---|---|
19/2/2024 | 13:58 | Location Sciences - mobile location intelligence | 862 |
15/2/2023 | 13:02 | LOCATION 🧠LOCATION 🧠LOCATION 🧠| 290 |
12/9/2020 | 07:58 | New Contract | 9 |
Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
---|
Top Posts |
---|
Posted at 13/12/2024 08:20 by Location Sciences Daily Update Location Sciences Group Plc is listed in the Mgmt Invt Offices, Open-end sector of the London Stock Exchange with ticker LSAI. The last closing price for Location Sciences was 134.38p.Location Sciences currently has 7,640,000 shares in issue. The market capitalisation of Location Sciences is £10,265,868. Location Sciences has a price to earnings ratio (PE ratio) of -5.95. This morning LSAI shares opened at - |
Posted at 30/1/2024 13:11 by ries Location Sciences Group PLC (LSE:LSAI, OTC:PXAMF) (LS) jumped 30% as it published details of its reverse takeover (RTO) by e-commerce tracking software specialist Sorted.The business will be called Sorted Group Holdings going forward with a new management team comprising Carmen Carey as chief executive and Mahmoud Warriah as CFO alongside Petar Cvetkovic as a non-executive director. LS shares are being consolidated on a 625 into 1 basis with a £2 million fundraising to follow the RTO at 87.5p a share. Sorted specialises in software for e-commerce delivery services for smaller, independent start-ups through to large, global enterprises such as Marks & Spencer, ASOS and Asda, all of which are customers. After a major reorganisation in 2021, Sorted implemented an automation programme and re-focused the business on shipping, tracking and returns. For the financial year ended 30 September 2023, Sorted's total unaudited revenue was approximately £6.5 million. Location Sciences shares rose 0.04p to 0.18p. |
Posted at 25/1/2024 07:47 by cancun tango Wow, that loan facility looks like a great deal. Unfortunately, it looks like a great deal for Bidco 3 not LSAI |
Posted at 14/1/2022 13:51 by plunge There is a lot of useful content and discussion on the Location Sciences #LSAI Telegram forum. You can always join it. |
Posted at 30/12/2021 09:02 by pwhite73 tima441 - "So the number of shares that are in free float might be just 10%"The number of shares that are in free float cannot be less than 25% and if any concerted party own more than 29.99% then they have to make a bid for the company unless the takeover rules are waived by the London Stock Exchange. The share price is clearly moving in the right direction and there may be things afoot but AIM/small cap companies are notorious for ripping off small shareholders no matter how small their percentage holding. For all the buying the price is making little progress suggesting there are large sellers in the background or placing shares are being forward sold at a discount. Having said all that I can understand why this would still be worth a small punt. |
Posted at 30/12/2021 09:00 by plunge Here is another enlightening post from Muck165 on the LSE chat forum.Always useful to look at time lines… Hughes/Kamani invest in Avacta early 2020 They shortly then set upM19, and get exclusive B2C rights, and non exclusive B2B rights to the Avacta test. M19 tried to get their own RSPT test away, but that seems to have failed, largely I think because it’s an antibody not an antigen test. Then in April it seems Hughes and Kamani lumped more cash into M19 Healthcare (see charges registered at companies house) In May they, with a concert group of family, Cheshire based investors, and notably Stephenson of M19, invest in LSAI, a business on its knees, ostensibly to drive the existing business. But shortly thereafter they give notice to the 2 remaining legacy Directors (promising to ensure they benefit from the EXISTING business), and begin to sell down assets. From June/July onwards M19 is like tumbleweed on social media..weird for sales and marketing experts. We now know that in this period their focus has been getting HUA for AffiDx, building Saturn Pass, and potentially also Agile. They trademarked Meduflow in November, but despite the HUA appear to have done next to nothing to promote it. Perhaps they don’t need to because of deals going on behind the scenes? Whatever, I’m convinced that there was zero reason for the concert party to buy into LSAI unless it was M19 linked, and the fact LSAI has £20m of prior trading losses to use may well have been a primary driver. |
Posted at 28/12/2021 21:44 by plunge We may see further upticks in the share price if punters (especially from the Avacta board) see LSAI as a potential play in tying up with Medusa 19. |
Posted at 28/12/2021 07:36 by tima441 What's the future hold? - not advice!Currently I think this is key....if my maths right...& lump Directors with Concert Party... - They currently have around 757m shs out of 2.6bil. Just under 30%. - If they exercise all warrants & options they will have around 2.7bil out of 4.6bil shs outstanding I.e. almost 60%. - 757m cost them approx £1.5m afaik - Roughly another 2bil will cost them around £4m. (most 0.2p.. some higher. Say another £4m cash into co. But will not exercise yet - as they will not want to bid What next? stressing this is just my guess: - Do a big placing at 1p (or more)... and buy @medusa19_ - Big placing at 1p... then trading at say 1.5p.... everyone happy!!!!! Potential Placing - Again stressing just a guess & idle musings: Issue 10bil shs at 1p = £100m cash Total shs out 12.6bil - Concert Party subscribe for 1.5bil new shs giving them 2.2bil in total (17.5%) but after exercise of options & warrants 4.2bil out of 12.6bil i.e. almost 30% (keeping under bid threshold) War-chest - £100m from placing - £4m from from warrants/options exercise Buy Medusa19 - Hughes & Kamani invested £20m in Dec 2020 & have built significant business including recently: AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU. - LSAI pay £50m(?) for Medusa19? - Possibly add Saturn Pass too? Other actions: - Rename LSAI as Medusa19 - Integrate Verify with SaturnPass if synergies exist? Or Divest previous business - Consolidate shares 10:1 so 1.26bil outstanding with say £50m cash - Possibly take stake(s) in one or more LFT manufacturer? (ABDX? ODX?) or better to remain ind from manufacturers? Enterprise value? 1.26 bil shs trading at say 15p = £189m mkt cap Concert Party 420m shs @ 15p = £63m Vs cost 270m @ 2p = £5.4m 150m @ 10p = £15m Total £20.4m Hughes/Kamani g I welcome feedback, comments or alternative views! |
Posted at 22/12/2021 11:10 by plunge Speculation on the other side suggesting a reverse takeover of Medusa 19 is in the offing.As long as the share price continues with an upward move, I will be happy with whatever transpires. |
Posted at 10/12/2021 15:46 by plunge From the link below, it looks like GeoProve is offering the exact same solution for validating location data that LSAI has done in the past.Now the question is, has it reinvented the wheel or has it acquired the technology from LSAI? My guess it's the latter but let us see. |
Posted at 31/1/2021 10:02 by sunshine today Fund1,Multiple today’s market cap by 10, and your market cap is only £46M. Your target is an tiny, extra £2.5M onto today’s market cap. LSAI 0.78P Mid 1/ Tiny market capitalisation, just £4.6M , of that , Net cash £1.2M. 2/ Analyst , two months ago , projected medium term, annual revenues of $50M . 3/ LSAI company presentations, 80% margins on verify software. ( Found on LSAI company, investor page.) 4/ Based on a reasonable growth PE of 20 , that would equate to LSAI having a Market capitalisation of over £500M. ( 100 times plus , current share price ) 4/ £19M unused tax loss 5/ New report 2021, from LSAI client, (InMarket) , with annual $100 revenues ( 2nd from last paragraph) We’re The First And Only Company To Offer Certified Location Audience Data: InMarket is the first and only company in the industry to offer certified Location Audience data, third-party verified for data accuracy and precision by the industry leader Location Sciences. Location Certified audiences build trust and allow brands to buy with confidence, knowing an independent third-party review has assured the precision and accuracy of the chosen audience. 2nd from last paragraph from the report. 5/ Finally: About Location Sciences Group PLC: (LSAI) Location Sciences is the pre-eminent global location verification provider to the $160 billion digital advertising industry. Working in partnership with brands, media agencies and suppliers to reduce ad-wastage and improve the effectiveness of location-based advertising campaigns. The digital advertising market-place remains unregulated and un-monitored, with an estimated $19 billion wasted on ad-fraud in 2018. Location Sciences has developed Verify, the world's first independent location verification product. Utilising sophisticated machine learning and pattern recognition technologies, Verify detects location ad-fraud and shines a light on location data inaccuracy with the aim of bringing back integrity, transparency and trust to the market place |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions